Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.743259
Keywords
elderly patients; ticagrelor; clopidogrel; acute coronary syndrome; meta-analysis
Categories
Funding
- National Natural Science Foundation of China [81873950, 82072144, 81772036, 81671952, 81873953, 82002017]
- National Key R&D Program of China [2020YFC1512700, 2020YFC1512705, 2020YFC1512703, 2020YFC0846600]
- National S&T Fundamental Resources Investigation Project [2018FY100600, 2018FY100602]
- Taishan Pandeng Scholar Program of Shandong Province [tspd20181220]
- Taishan Young Scholar Program of Shandong Province [tsqn20161065, tsqn201812129]
- Key R&D Program of Shandong Province [2019GSF108075, 2018GSF118003]
- Interdisciplinary Young Researcher Groups Program of Shandong University [2020QNQT004]
- Fundamental Research Funds of Shandong University [2018JC011]
Ask authors/readers for more resources
In elderly patients with ACS, aspirin plus ticagrelor reduces the risk of cardiovascular death and all-cause mortality but increases the risk of bleeding. Compared to clopidogrel, aspirin plus ticagrelor may prolong the lifetime of elderly ACS patients. The optimal dual antiplatelet therapy for elderly ACS patients may be a valuable direction for future research.
Background: Dual antiplatelet therapy combining aspirin with a P2Y12 adenosine diphosphate receptor inhibitor is a therapeutic mainstay for acute coronary syndrome (ACS). However, the optimal choice of P2Y12 adenosine diphosphate receptor inhibitor in elderly (aged >= 65 years) patients remains controversial. We conducted a meta-analysis to compare the efficacy and safety of ticagrelor and clopidogrel in elderly patients with ACS. Methods: We comprehensively searched in Web of Science, EMBASE, PubMed, and Cochrane databases through 29(th) March, 2021 for eligible randomized controlled trials (RCTs) comparing the efficacy and safety of ticagrelor or clopidogrel plus aspirin in elderly patients with ACS. Four studies were included in the final analysis. A fixed effects model or random effects model was applied to analyze risk ratios (RRs) and hazard ratios (HRs) across studies, and I-2 to assess heterogeneity. Results: A total number of 4429 elderly patients with ACS were included in this analysis, of whom 2170 (49.0%) patients received aspirin plus ticagrelor and 2259 (51.0%) received aspirin plus clopidogrel. The ticagrelor group showed a significant advantage over the clopidogrel group concerning all-cause mortality (HR 0.78, 95% CI 0.63-0.96, I-2 = 0%; RR 0.79, 95% CI 0.66-0.95, I-2 = 0%) and cardiovascular death (HR 0.71, 95% CI 0.56-0.91, I-2 = 0%; RR 0.76, 95% CI 0.62-0.94, I-2 = 5%) but owned a higher risk of PLATO major or minor bleeding (HR 1.46, 95% CI 1.13-1.89, I-2 = 0%; RR 1.40, 95% CI 1.11-1.76, I-2 = 0%). Both the groups showed no significant difference regarding major adverse cardiovascular events (MACEs) (HR 1.06, 95% CI 0.68-1.65, I-2 = 77%; RR 1.04, 95% CI 0.69-1.58, I-2 = 77%). Conclusion: For elderly ACS patients, aspirin plus ticagrelor reduces cardiovascular death and all-cause mortality but increases the risk of bleeding. Herein, aspirin plus ticagrelor may extend lifetime for elderly ACS patients compared with aspirin plus clopidogrel. The optimal DAPT for elderly ACS patients may be a valuable direction for future research studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available